In alternative embodiments, the invention provides a “
triple combination” therapy for treating, ameliorating and preventing Crohn's
Disease (or Crohn syndrome, terminal or distal ileitis or regional
enteritis) or related disorders and conditions in mammals, such as
paratuberculosis in mammals, or Johne's
disease, including genetically-predisposed and
chronic disorders, where the microbial or bacterial
flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's
Disease or
paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's
Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as
paratuberculosis in mammals, or Johne's
disease, comprises administration to an individual (human or
mammal) in need thereof: (1) an anti-TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a
Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti-
Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.